<DOC>
	<DOC>NCT01515657</DOC>
	<brief_summary>This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.</brief_summary>
	<brief_title>Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Adults 2179 Body mass index (BMI) of 3040 kg/m2 Noninsulindependent type2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of &gt; 6.4% and/or fasting plasma glucose of &gt;125 mg/dL or current antidiabetic medication) AAinduced platelet aggregation response of &gt;60% within 3 hours prior to initial dose of study drug administration Contraindications to aspirin Previous history of vascular disease Patient requires insulin Use of nonsteroidal antiinflammatory drugs, antisecretory agents, antacids, and salicylatecontaining nutritional supplements within 2 weeks of randomization</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>